| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 8
| Issue : 2 | Page : 65-67 |
|
|
Crizotinib in treatment of lung cancer
Arpita Singh1, Anubhuti Singh2, Kislay Kishore3, Ajay K Verma2, Surya Kant2
1 Department of Pharmacology, Government Medical College, Kannauj, Uttar Pradesh, India
2 Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India
3 Department of Respiratory Medicine, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India
Correspondence Address:
Surya Kant
Department of Respiratory Medicine, King George's Medical University, Chowk, Lucknow - 226 003, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/mjmsr.MJMSR_62_16
|
|
|
Lung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is indicated in the treatment of patients with locally advanced or metastatic? non small cell lung carcinoma (NSCLC) harboring ALK mutation as a targeted therapy. This is short drug review of crizotinib in the treatment of advanced lung cancer. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
